The title compound, [Rh(C(5)H(7)O(2))(C(18)H(12)Cl(3)P)(CO)], contains the bidentate acetyl-acetonate ligand coordinated to the Rh(I) atom, forming a chelate ring [Rh-O = 2.0327 (15) and 2.0613 (14) Å]. The Rh(I) atom is additionally coordinated by one P [Rh-P = 2.2281 (6) Å] and one carbonyl C [Rh-C = 1.812 (2) Å] atom, resulting in a slightly distorted square-planar geometry. The mol-ecules a...

In the title complex, [Co(C(16)H(15)N(2)O)(C(10)H(9)O(2))(N(3))], the Co(II) atom adopts an octa-hedral coordination geometry by a tridentate Schiff base, a bidentate benzoyl-acetonate and an azide ligand. The imine N atom of the tridentate ligand is trans to the benzoyl O atom of the bidentate ligand and the azide ligand is trans to the acetyl O atom of the bidentate ligand. Non-classical intr...

In the title compound, [Re(C(5)H(4)F(3)O(2))(C(5)H(5)N)(CO)(3)], the Re(I) atom is six-coordinated owing to bonding by three carbonyl ligands arranged in a fac configuration, two O atoms from the bidentate 1,1,1-trifluoro-acetyl-acetonate ligand and an N atom from a pyridine ligand. In the crystal, the mol-ecules pack in layers, diagonally, in a head-to-tail fashion across the ab plane. These l...

In the title compound, [Cu(C(5)H(7)O(2))(C(2)N(3))(C(12)H(8)N(2))]·2H(2)O, the Cu(II) atom is five-coordinated in a square-pyramidal geometry with two acetyl-acetonate O and two phenanthroline N atoms forming the base. The apical position is occupied by the central N atom of the dicyanamide ligand. The dicyanamide N atoms are each involved in hydrogen bonds to water mol-ecules. There are also h...

The title complex, [Fe4(C5H7O2)4(CH3O)6Cl2] or [Fe4(acac)4(μ2-OMe)4(μ3-OMe)2Cl2] (acac = acetyl-acetonate), crystallizes in the ortho-rhom-bic Pbca space group with one half of the mol-ecule per asymmetric unit, the other half being completed by inversion symmetry. The core structure consists of a face-sharing double pseudo-cubane entity with two opposite corners missing. Weak C-H⋯Cl inter-mole...

BACKGROUND/AIMS Treatment with intralesional triamcinolone/betamethasone is recommended for infantile sight-threatening periocular haemangiomas. This study investigates the endocrine and weight changes in 15 infants undergoing therapy over 12 years. METHODS 15 infants, median age 19 weeks (range 10-56) receiving intra/perilesional triamcinolone/betamethasone underwent serial measurement of we...

PURPOSE To report the use of intravitreal triamcinolone for Susac Syndrome in one patient. METHODS Case report. RESULTS A 23-year-old woman presented with presented with sudden visual loss in the left eye with associated neurologic symptoms. Ophthalmic examination and fluorescein angiography showed multiple areas of branch retinal artery occlusion, bilaterally. Magnetic resonance imaging sh...

PURPOSE To report a case of retinal capillary hemangioma treated with verteporfin photodynamic therapy combined with intravitreal triamcinolone acetonide. METHODS A 15-year-old female presented with metamorphopsia in the left eye for 7 days. Examination showed peripheral endophytic retinal capillary hemangioma, macular edema, and a best-corrected visual acuity of 20/50. The hemangioma and mac...

Male Fischer 344 rats were given a single lung instillation of bleomycin sulfate (0.6 units/100 g). some animals were treated 24 hr after bleomycin administration with triamcinolone diacetate. Steroid treatment was continued on alternate days for 4 weeks. At the end of 4 weeks, the lungs of rats receiving bleomycin alone had two-fold increases of both prolyl hydroxylase activity and proteinaceo...

The purpose is to report a complication after photodynamic therapy (PDT) and intravitreal triamcinolone for a presumed choroidal neovascularization in age-related macular degeneration. Photodynamic therapy and intravitreal triamcinolone were used in an 84-year-old man with choroidal neovascularization in the left eye. Forty-five days after therapy, the patient returned with a severe necrotizing...